公开(公告)号：US11744833B2

公开(公告)日：2023-09-05

申请号：US17673136

申请日：2022-02-16

Applicant: LA PharmaTech Inc.

Inventor： Jianmin Wang ,  Fengyuan Jia

IPC: A61K31/55 ,  A61K31/4045 ,  A61P25/20

CPC classification number: A61K31/55 ,  A61K31/4045 ,  A61P25/20

Abstract: Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and melatonin are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from insomnia are also disclosed.

公开(公告)号：US11730750B2

公开(公告)日：2023-08-22

申请号：US17178096

申请日：2021-02-17

Applicant: University of Kentucky Research Foundation

Inventor： Vivek M. Rangnekar ,  Ravshan Burikhanov ,  David S. Watt

IPC: A61K31/7048 ,  A61K45/06 ,  A61K31/4706 ,  A61K31/704 ,  A61K31/55 ,  A61K31/4545 ,  A61K31/675 ,  A61K31/497 ,  A61K31/517 ,  A61K31/4745

CPC classification number: A61K31/7048 ,  A61K31/4545 ,  A61K31/4706 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/517 ,  A61K31/55 ,  A61K31/675 ,  A61K31/704 ,  A61K45/06

Abstract: A method of treating cancer in an individual includes a step of administering to the individual a pharmaceutically effective amount of (a) a first active agent adapted for producing secretion of prostate apoptosis response-4 (Par-4) from normal cells and (b) a second active agent adapted for elevating GRP78 receptors for Par-4 on a surface of a cancer cell in the individual.

公开(公告)号：US11701358B2

公开(公告)日：2023-07-18

申请号：US16487239

申请日：2018-02-14

Applicant: Indiana University Research and Technology Corporation ,  Universita Magna Graecia (UMG) at Catanzaro ,  Lead Discovery Siena

Inventor： Bonnie L. Blazer-Yost ,  Nicola Perrotti ,  Silvia Schenone

IPC: A61K31/519 ,  A61K9/00 ,  A61K31/11 ,  A61K31/145 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4965 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/585

CPC classification number: A61K31/519 ,  A61K9/0053 ,  A61K31/11 ,  A61K31/145 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4965 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/585

Abstract: Methods of using serum glucocorticoid induced kinase 1 (SGK1) inhibitors for reducing the development of diseases related to salt and water balance, and in particular, hydrocephalus and/or hypertension, are disclosed herein. Particularly, the present disclosure is directed to the use of SGK1 inhibitors to inhibit transepithelial ion transport, such as in one embodiment, in the choroid plexus of a subject, thereby reducing cerebrospinal fluid (CSF) production or, alternatively, in another embodiment, to inhibit transepithelial sodium transport in the kidney collecting duct thereby reducing sodium reabsorption into the blood.

公开(公告)号：US11690849B2

公开(公告)日：2023-07-04

申请号：US17459868

申请日：2021-08-27

Applicant: LA PharmaTech Inc.

Inventor： Jianmin Wang ,  Geping Cui

IPC: A61K31/55 ,  A61P25/28 ,  A61K9/00

CPC classification number: A61K31/55 ,  A61K9/0053 ,  A61P25/28

Abstract: Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine are disclosed.

公开(公告)号：US20230201217A1

公开(公告)日：2023-06-29

申请号：US18174063

申请日：2023-02-24

Applicant: Mind Medicine, Inc.

Inventor： Scott FREEMAN ,  Stots B. REELE ,  Jeanne BONELLE

IPC: A61K31/55 ,  A61P25/30 ,  A61K9/00

CPC classification number: A61K31/55 ,  A61P25/30 ,  A61K9/0053

Abstract: A composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier. A method of treating substance use disorders, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A method of preventing addictive behavior in an individual. A method of preventing craving in an individual. A composition of a metabolite of 18-MC salt. A method of treating substance use disorders by administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A composition having various pharmacokinetic profiles as shown in the Figures.

公开(公告)号：US11684609B2

公开(公告)日：2023-06-27

申请号：US15892204

申请日：2018-02-08

Applicant: The Regents Of The University Of California

Inventor： Scott C. Baraban

IPC: A61K31/4184 ,  A61K31/137 ,  A61K31/20 ,  A61K31/27 ,  A61K31/473 ,  A61K31/551 ,  A61K31/7048 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/357 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/433 ,  A61K31/55 ,  A61K31/5513 ,  A61K33/00 ,  A61K45/06

CPC classification number: A61K31/4184 ,  A61K31/137 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/357 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/433 ,  A61K31/473 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/7048 ,  A61K33/00 ,  A61K45/06 ,  A61K31/4184 ,  A61K2300/00 ,  A61K31/433 ,  A61K2300/00 ,  A61K31/551 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00 ,  A61K31/195 ,  A61K2300/00 ,  A61K31/473 ,  A61K2300/00 ,  A61K31/197 ,  A61K2300/00 ,  A61K31/7048 ,  A61K2300/00 ,  A61K31/20 ,  A61K2300/00

Abstract: Provided, inter alia, are methods for treating an epilepsy disorder using clemizole, a clemizole analog, or pharmaceutical salts thereof.

公开(公告)号：US20230191047A1

公开(公告)日：2023-06-22

申请号：US18082311

申请日：2022-12-15

Applicant: Belhaven BioPharma Inc.

Inventor： Scott Lyman ,  Barry Bleske

IPC: A61M15/08 ,  A61K9/00 ,  A61K9/16 ,  A61K31/55 ,  A61K31/137 ,  A61K31/5513 ,  A61K31/46 ,  A61K31/4425 ,  A61K31/417 ,  A61K31/277 ,  A61K31/13

CPC classification number: A61M15/08 ,  A61K9/0043 ,  A61K9/1652 ,  A61K9/1623 ,  A61K9/1611 ,  A61K31/55 ,  A61K31/137 ,  A61K31/5513 ,  A61K31/46 ,  A61K31/4425 ,  A61K31/417 ,  A61K31/277 ,  A61K31/13 ,  A61M2209/06 ,  A61M2205/3327

Abstract: Provided herein are dry powder formulations comprising at least one active pharmaceutical ingredient suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including respiratory conditions, hemodynamic collapse, seizures, migraines, and other conditions.

公开(公告)号：US20230183247A1

公开(公告)日：2023-06-15

申请号：US17932876

申请日：2022-09-16

Applicant: AKARNA THERAPEUTICS, LTD.

Inventor： Benjamin Anthony Pratt ,  Raju Mohan

IPC: C07D487/04 ,  A61P3/06 ,  A61P3/04 ,  A61K31/55 ,  A61P3/10

CPC classification number: C07D487/04 ,  A61P3/06 ,  A61P3/04 ,  A61K31/55 ,  A61P3/10

Abstract: Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.

公开(公告)号：US20230181594A1

公开(公告)日：2023-06-15

申请号：US17813728

申请日：2022-07-20

Applicant: Johnson & Johnson Vision Care, Inc.

Inventor： Avner Ingerman ,  Frans Janssens ,  Anton Megens ,  Mark B. Abelson

IPC: A61K31/55 ,  A61K9/00 ,  A61K9/08

CPC classification number: A61K31/55 ,  A61K9/0048 ,  A61K9/08

Abstract: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230181583A1

公开(公告)日：2023-06-15

申请号：US17985740

申请日：2022-11-11

Applicant: Terns Pharmaceuticals, Inc.

Inventor： Christopher T. JONES ,  Martijn FENAUX ,  Yujin WANG ,  Feng JIN ,  D. Barry CRITTENDEN ,  Erin K. QUIRK

IPC: A61K31/506 ,  A61K31/454 ,  A61K31/55 ,  A61K31/355 ,  A61K31/575 ,  A61K31/732 ,  A61K38/05 ,  A61P1/16

CPC classification number: A61K31/506 ,  A61K31/454 ,  A61K31/55 ,  A61K31/355 ,  A61K31/575 ,  A61K31/732 ,  A61K38/05 ,  A61P1/16

Abstract: Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient comprising administration of the SSAO inhibitor:




or a pharmaceutically acceptable salt thereof.